Avicena receives patent in Australia for use of creatine for skin preservation

By Lisa Kerner

Erie, Pa., April 26 - The Avicena Group, Inc. said it has been granted a patent (number 09/344427) entitled "Use of Creatine or Creatine Compounds for Skin Preservation" from the Commonwealth of Australia's Patent Office.

The company has already secured patent protection for this use in the United States (U.S. Patent No. 6,242,491 B1), and a similar patent application is presently pending in Europe.

"This newly granted patent represents a key addition to our present intellectual property portfolio as it provides us with increased protection in the area of skin care, as well as additional momentum for this component of our business," chief executive officer Belinda Tsao-Nivaggioli said in a company news release.

"This is important as our dermaceutical business will play a critical role in our overall business strategy and help complement our ongoing work in pharmaceuticals and nutraceuticals."

Avicena said it is commercializing therapeutic ingredients and formulations to enhance cellular regeneration and repair as well as treat causes of premature skin aging by providing a healthy skin cell environment.

Avicena is a biotechnology company based in Palo Alto, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.